AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer

The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer – making it the first drug approved in the EU for this condition, and the third EU indication overall for what is becoming a key drug for the two companies.